Seattle genetics announces potential accelerated approval pathway in the u.s. for padcev™

Seattle genetics announces potential accelerated approval pathway in the u.s. for padcev™ (enfortumab vedotin-ejfv) in combination with immune therapy pembrolizumab as first-line treatment for advanced urothelial cancer.seattle genetics - padcev with pembrolizumab could potentially support registration under accelerated approval regulations in united states.
SGEN Ratings Summary
SGEN Quant Ranking